We are no longer accepting Byetta cases
Manufactured by Amylin Pharmaceuticals and Eli Lilly and Co., the diabetes drug Byetta® has been linked to an increased risk of pancreatic cancer.
A study published in the medical journal Gastroenterology concluded that patients who took the injectable Byetta developed higher risk of pancreatic cancer, according to adverse event reports filed with the U.S. Food and Drug Administration (FDA) between 2004-2009. These patients had nearly a three-fold increase in risk of developing the disease than individuals utilizing another treatment method.
Further analysis published by JAMA Internal Medicine described 1,200 diabetes patients who were hospitalized for pancreatitis, 87 of which had filled an oral prescription for Byetta to treat their condition.
If you or someone you love were diagnosed with pancreatic cancer after taking Byetta, you may be entitled to compensation for your medical bills, lost wages, and pain and suffering.
Cory Watson Attorneys is prepared to file Byetta lawsuits for victims like you, and we’re ready to help 24/7. Call (877) 562-0000 or complete a free initial consultation form now to find out how we can help. There is no obligation to proceed, it is always confidential, and there’s no cost for us to review your case.
Lawsuits Claim Byetta® Is Dangerous
Pancreatic cancer is an aggressive disease that is extremely resistant to treatment. Plaintiffs who have filed lawsuits against Byetta’s manufacturers, Amylin Pharmaceutical and Eli Lilly and Co., allege that the drug lowers Glucagon-like Peptide 1 (GLP1) levels in diabetes patients to the point that they are susceptible to pancreatic cancer.
In addition, the plaintiffs allege the following claims:
- Byetta is inherently defective based on its blend of ingredients which increase a patient’s risk of developing pancreatic cancer.
- Amylin Pharmaceuticals and Eli Lilly and Co. were negligent in failing to adequately warn consumers of this risk.
- Amylin Pharmaceuticals and Eli Lilly and Co. hid their knowledge of Byetta’s possible link to pancreatic cancer.
- The warning label on Byetta still does not adequately address its risks.
- Byetta’s risks outweigh its benefits, as other available treatment options do not carry the risk of pancreatic cancer.
- Had the FDA known about Byetta’s link to pancreatic cancer the drug may not have been approved for registration and sale.
In August 2013, class action litigation against the manufacturers was consolidated into a multidistrict litigation (MDL) case, and as of September 2013 there were 60 individual cases pending as part of this MDL.
Contact a Byetta® Injury Lawyer
Our firm believes that the rights of patients who took the defective drug Byetta need to be defended. At Cory Watson Attorneys, we always fight for the maximum amount of compensation for our clients. And because we work on a contingency fee basis, you pay us nothing unless we recover a successful verdict or settlement for you.
For 24/7 help with your Byetta injury claim, call Cory Watson Attorneys at (877) 562-0000 or fill out the free initial consultation form.
Byetta® is a registered trademark of Amylin Pharmaceutical and Eli Lilly and Co. and is used here only to identify the product in question.
This law firm is not associated with, sponsored by, or affiliated with Amylin Pharmaceutical; Eli Lilly and Co.; Gastroenterology; JAMA Internal Medicine; or the U.S. Food and Drug Administration.